Table of Contents
ISRN Neurology
Volume 2013, Article ID 748127, 8 pages
http://dx.doi.org/10.1155/2013/748127
Clinical Study

Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone

1St. Petersburg’s Center of MS and Autoimmune Diseases, City Hospital N31, Saint Petersburg, Russia
2Department of Rheumatology, Federal Clinical Center of Heart, Blood and Endocrinology, Saint Petersburg, Russia
3Laboratory of Autoimmune Diagnostics, Saint-Petersburg Pavlov Medical University, Saint Petersburg, Russia
4Department of Neurology, Leningrad Region Hospital, Saint Petersburg, Russia
5Neuroimmunology Group, Blizard Institute, Great Britain, UK
6Laboratory of Immunology, Pasteur Institute for Microbiology and Epidemiology, Saint Petersburg, Russia
7Department of Neurology, Saint-Petersburg Pavlov Medical University, Saint Petersburg, Russia
8Department of Neurology and Neurosurgery and Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada

Received 16 July 2013; Accepted 9 August 2013

Academic Editors: R. Beschorner and R. Saponara

Copyright © 2013 Evgeniy Evdoshenko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. D. Jacobs, D. L. Cookfair, R. A. Rudick et al., “Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis,” Annals of Neurology, vol. 39, no. 3, pp. 285–294, 1996. View at Google Scholar · View at Scopus
  2. K. P. Johnson, B. R. Brooks, J. A. Cohen et al., “Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double- blind, placebo-controlled trial,” Neurology, vol. 45, no. 7, pp. 1268–1276, 1995. View at Google Scholar · View at Scopus
  3. R. A. Farrell and G. Giovannoni, “Current and future role of interferon beta in the therapy of multiple sclerosis,” Journal of Interferon and Cytokine Research, vol. 30, no. 10, pp. 715–726, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Giovannoni, G. Comi, S. Cook et al., “A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis,” The New England Journal of Medicine, vol. 362, no. 5, pp. 416–426, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Giovannoni, R. P. Kinkel, and T. Vartanian, “Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices,” Reviews in Neurological Diseases, vol. 4, no. 4, pp. 184–193, 2007. View at Google Scholar · View at Scopus
  6. R. A. Rudick, D. Miller, S. Hass et al., “Health-related quality of life in multiple sclerosis: effects of natalizumab,” Annals of Neurology, vol. 62, no. 4, pp. 335–346, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. B. C. Kieseier and D. R. Jeffery, “Chemotherapeutics in the treatment of multiple sclerosis,” Therapeutic Advances in Neurological Disorders, vol. 3, no. 5, pp. 277–291, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. C. W. Edwards, L. Szczepański, J. Szechiński et al., “Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis,” The New England Journal of Medicine, vol. 350, no. 25, pp. 2572–2581, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. F. C. Fervenza, “Rituximab in ANCA-associated vasculitis: fad or fact?” Nephron, vol. 118, no. 2, pp. c182–c188, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Garcia-Valladares and L. R. Espinoza, “Is rituximab superior to cyclophosphamide for ANCA-associated vasculitis for induction of remission, and with a better safety profile?” Current Rheumatology Reports, vol. 12, no. 6, pp. 395–398, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. U. Schönermarck and K. de Groot, “Vasculitis: rituximab: effective in ANCA-associated vasculitis?” Nature Reviews Nephrology, vol. 7, no. 1, pp. 6–8, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Holmøy, “Immunopathogenesis of multiple sclerosis: concepts and controversies,” Acta Neurologica Scandinavica, vol. 115, no. 187, pp. 39–45, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. S. L. Hauser, E. Waubant, D. L. Arnold et al., “B-cell depletion with rituximab in relapsing-remitting multiple sclerosis,” The New England Journal of Medicine, vol. 358, no. 7, pp. 676–688, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. A. E. Walsh, U. Fearon, O. FitzGerald, D. J. Veale, and B. Bresnihan, “Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy,” Clinical and Experimental Rheumatology, vol. 26, no. 4, pp. 656–658, 2008. View at Google Scholar · View at Scopus
  15. Y. K. Teng, E. W. Levarht, R. E. Toes, T. W. Huizinga, and J. M. van Laar, “Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation,” Annals of the Rheumatic Diseases, vol. 68, no. 6, pp. 1011–1016, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Le Page, E. Leray, G. Taurin et al., “Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 1, pp. 52–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Komori, T. Kondo, and M. Tanaka, “Mitoxantrone for the treatment of patients with multiple sclerosis,” Brain and Nerve, vol. 61, no. 5, pp. 575–580, 2009. View at Google Scholar · View at Scopus
  18. S. C. Ridge, A. E. Sloboda, and R. A. McReynolds, “Suppression of experimental allergic encephalomyelitis by mitoxantrone,” Clinical Immunology and Immunopathology, vol. 35, no. 1, pp. 35–42, 1985. View at Google Scholar · View at Scopus
  19. B. Bellosillo, D. Colomer, G. Pons, and J. Gil, “Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B- chronic lymphocytic leukaemia cells,” British Journal of Haematology, vol. 100, no. 1, pp. 142–146, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Duddy, M. Niino, F. Adatia et al., “Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis,” Journal of Immunology, vol. 178, no. 10, pp. 6092–6099, 2007. View at Google Scholar · View at Scopus
  21. M. Duddy and A. Bar-Or, “B-cells in multiple sclerosis,” International MS Journal, vol. 13, no. 3, pp. 84–90, 2006. View at Google Scholar · View at Scopus
  22. S. Faderl, W. Wierda, S. O'Brien, A. Ferrajoli, S. Lerner, and M. J. Keating, “Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years,” Leukemia Research, vol. 34, no. 3, pp. 284–288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. C. H. Polman, S. C. Reingold, G. Edan et al., “Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’,” Annals of Neurology, vol. 58, no. 6, pp. 840–846, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. “Common Terminology Criteria for Adverse Events v3. 0 (CTCAE),” http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
  25. A. Trotti, A. D. Colevas, A. Setser et al., “CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment,” Seminars in Radiation Oncology, vol. 13, no. 3, pp. 176–181, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. C. H. Hawkes, E. J. Thompson, G. Keir et al., “Iso-electric focusing of aqueous humour IgG in multiple sclerosis,” Journal of Neurology, vol. 241, no. 7, pp. 436–438, 1994. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard, “Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma,” Clinical Cancer Research, vol. 13, no. 18, pp. 5636–5642, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. RITUXIMAB, package insert. Biogen Idec Inc and Genentech, Inc. PI Revision Date 04, 2011.
  29. T. Papadaki, K. Stamatopoulos, A. Anagnostopoulos, and A. Fassas, “Rituximab-associated immune myelopathy,” Blood, vol. 102, no. 4, pp. 1557–1558, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Papadaki, K. Stamatopoulos, N. Stavroyianni, G. Paterakis, M. Phisphis, and K. Stefanoudaki-Sofianatou, “Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases,” Leukemia Research, vol. 26, no. 6, pp. 597–600, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Voog, F. Morschhauser, P. Solal-Céligny, M. C. Benyunes, P. S. Multani, and A. Saunders, “Neutropenia in patients treated with rituximab,” The New England Journal of Medicine, vol. 348, no. 26, pp. 2691–2694, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Terrier, M. Ittah, L. Tourneur et al., “Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery,” Haematologica, vol. 92, no. 2, pp. e20–e23, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Kingwell, M. Koch, B. Leung et al., “Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS,” Neurology, vol. 74, no. 22, pp. 1822–1826, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Comi, “Induction versus escalating therapy in multiple sclerosis: practical implications,” Neurological Sciences, vol. 29, supplement 2, pp. S253–S255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. A. J. Coles, E. Fox, A. Vladic et al., “Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes,” The Lancet Neurology, vol. 10, no. 4, pp. 338–348, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. D. M. Harrison, D. E. Gladstone, E. Hammond et al., “Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance,” Multiple Sclerosis, vol. 18, no. 2, pp. 202–209, 2012. View at Publisher · View at Google Scholar · View at Scopus